Selank Protocol: The Sequence the Research Followed

The real Selank protocol is a development sequence, not a numbered schedule: a synthetic peptide derived from tuftsin, taken through animal work and clinical work in Russia, and ending in registration as a medicine there. That sequence finished inside one jurisdiction and was never started in the Western system, which is why there is no trial identifier to cite anywhere on this page. Following the order it ran in explains almost everything that confuses people about this compound.

From tuftsin to a registered medicine

Each step in a development programme answers a question raised by the step before it, and the questions are worth naming.

It began with tuftsin, a peptide the body produces. Building a synthetic derivative of an endogenous peptide is standard pharmaceutical reasoning: something the body already makes is a template with known activity, and modification aims at making it usable and stable enough to be a medicine. That is where the molecule comes from.

Then came laboratory and animal work in Russia, aimed at anxiety from early on rather than at a general purpose. That focus matters. Compounds whose claimed effects fan out in all directions usually acquired those claims after the fact, from marketing. This one had a target its own developers named at the start, and the literature stayed close to it.

Then came clinical work in humans, conducted within that system, using the methods psychiatric outcomes require: rating scales applied by clinicians, because there is no blood test for anxiety.

Then came registration. Selank is a registered medicine in Russia, which means a regulator there reviewed a file and authorised a product with labelling attached. That is a real status and the clinical literature behind it is real.

And then the sequence stopped. Nothing equivalent was run in the Western system. There is no FDA, EMA or MHRA authorisation, and no genuine registered Western trial.

What the animal work specified, and what it leaves out

The animal layer deserves its own description, because it is where mechanism claims come from and where they get over read.

Rodent studies of anxiety related behaviour use standard behavioural tests. An animal's movement through an open area, its willingness to enter exposed space, its response to unfamiliar surroundings. Animals receiving the compound are compared against a control group, the interval is fixed in advance, and the outcome is a behavioural score.

Those are real measurements of rat and mouse behaviour. They are not reports of experience, because a rodent reports nothing. Researchers interpret the behavioural change as anxiety related, which is a standard and reasonable interpretation and is still an interpretation.

Mechanistic work in rodent tissue has described effects on brain signalling systems associated with mood, and there is reported work on enkephalin breakdown observed in human blood samples. Both describe a possible route rather than an outcome in a person, and both get quoted as though they were results.

What none of the animal work can supply is a human schedule. An animal protocol specifies dosing per kilogram of body weight, an experiment with a defined start, and a measurement at a scheduled end. None of those three anchors exists for someone at home.

What a Selank protocol in the Western sense would require

Being specific about the missing document is more useful than saying evidence is limited.

It would be registered publicly before enrolment, so its existence is on record whether or not the results please anyone. It would specify who may enrol and who may not, and the exclusion criteria would be roughly half the document. It would fix a primary outcome and a rating scale in advance, so nothing can be chosen afterwards because it happened to move. It would include a placebo group, because self reported outcomes like anxiety respond strongly to expectation. It would blind participants and assessors. It would define monitoring and stopping rules, and name who decides. It would have an accountable sponsor. And its results would be published where people with no stake in them can read and criticise them.

Not one of those elements is present in the schedules circulating in English. Those documents have quantities and intervals, which is the part that looks like a protocol, and none of the structure that makes a protocol worth following.

Why the sequence never started in the West

Worth addressing, because readers reasonably wonder whether absence means rejection.

It does not, and the difference matters. Nothing in the record indicates that a Western regulator reviewed this compound and turned it down. A regulator cannot reject a file that was never submitted, and running the trial programme required to submit one is expensive, slow, and undertaken by parties with a commercial reason to undertake it. Compounds developed in one jurisdiction frequently never cross into another for reasons of patent position, market size and corporate ownership rather than because of any judgement on their merits.

So the honest reading is that the question was never asked in the Western system, rather than asked and answered badly. That cuts both ways. It removes one reason for suspicion, and it removes any basis for claiming Western evidence exists.

The two documents a reader keeps confusing

It is worth putting the two side by side one more time, because the confusion between them is not carelessness. It is produced by the vocabulary.

The first document is a regulatory dossier: the file a manufacturer assembles and a regulator reviews, containing the animal work, the clinical work, the manufacturing detail, and the proposed labelling. It runs to thousands of pages, most of which nobody outside the process ever reads. Its output is an authorisation and a label, and it exists for this compound in one country.

The second document is a page on a supplier's site with a heading, some quantities and an interval. It is written to be read in ninety seconds by somebody who has already decided to buy.

Both get called a protocol in English, and that single shared word carries the authority of the first onto the second. The reader who finds the second one has no way of knowing it is not a summary of the first, because it is written in the register of one.

The tell is what the document is willing to say no to. A regulatory label spends most of its length on restrictions: who must not take it, what must not be taken alongside it, what to do if something goes wrong. A schedule written to sell says no to nothing, because every restriction removes a customer.

Reading a schedule you find online

Given all of the above, a short set of checks does most of the work.

Ask who wrote it. If there is no name and no institution, there is nobody to hold to it, and the confidence of the writing is unrelated to its basis.

Ask what it applies to. A schedule descended from the Russian labelling applies to a manufactured product with verified contents, not to a research chemical vial with none.

Ask what it leaves out. Contraindications, warnings, and who should not take it are the parts that vanish first in copying, and they are the parts a regulator spends the most time on.

And ask how it ends. A protocol specifies what gets measured at the finish and what decision follows. A schedule that ends with an impression has no evaluation step at all.